Companies · Pharma

Vin-5 Nob Hill Therapeutics, Llc

FAYETTEVILLE · Pharma · refined from filed group “Other”

Diligence memoA one-page analyst read on Vin-5 Nob Hill Therapeutics, Llc — recommendation, valuation, rhythm, risks.→
$113K
Total raised · real
1
Rounds
—
Latest step-up
Top 83%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Oct 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Vin-5 Nob Hill Therapeutics, Llc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.38× the median modeled value of Pre-Seed Pharma companies in 2016–2018 (20 peers) — value vs value, same stage and era.
Dormant
  • Last raise 9.7 yr ago; this sector typically re-raises about every 16 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Vin-5 Nob Hill Therapeutics, Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.9 yr record
Peak capital year was 2016 with $113K across 1 filings.
Market position
ahead of 18% of Pharma peers
Capital scale is ahead of 18% of Pharma peers; modeled value is above 27% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2016: $113K across 1 filings.
  • Largest single filing was $113K on 2016-10-26.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharma

Vin-5 Nob Hill Therapeutics, Llc is one of 310 Pharma companies tracked from FAYETTEVILLE. By capital raised it ranks in the long tail (ahead of 18% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
13
Investors (latest)
2016
Year incorporated
2016-10-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2016-10-26 Raised $113K (real) Modeled valuation $5.3M (est)$113K$5.3MPre-Seed2016

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$113K · 2016

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$5.3M
Base estimate est.
$63K
Conservative case
$60.3M
Upside case
$625K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
9.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
9.9 yr
On record since
2016
First round
1
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.0× of median
This company$113K
Sector median$6.4M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage)▼ 0.4× of median
This company$113K
Sector median$307K
Modeled value — vs sector median (estimate, all stages)▼ 0.1× of median
This company$5.3M
Sector median$62.5M

Raised more than 18% of sector peers (real $). Modeled value above 27% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 20.

This companyCohort peer
$1.0M$10.0M$100.0M$10K$100K$1.0M$10.0MCapital raised (log)vivo-TIL Therapeutics, Inc · Pre-Seed Raised $990K · modeled $46.8M (est)JSK Therapeutics, Inc. · Pre-Seed Raised $963K · modeled $45.5M (est)Kyto Biopharma Inc · Pre-Seed Raised $845K · modeled $40.0M (est)Manzara Therapeutics, Inc. · Pre-Seed Raised $750K · modeled $35.5M (est)Mirata BioPharma, LLC · Pre-Seed Raised $500K · modeled $23.7M (est)Avery Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $23.7M (est)Senolytic Therapeutics, Inc. · Pre-Seed Raised $500K · modeled $23.7M (est)Chaperone Therapeutics, Inc. · Pre-Seed Raised $457K · modeled $21.6M (est)AR Pharma, Inc. · Pre-Seed Raised $410K · modeled $19.4M (est)Disrupt Pharma Tech Africa, Inc. · Pre-Seed Raised $330K · modeled $15.6M (est)Sante Veritas Therapeutics Inc · Pre-Seed Raised $267K · modeled $12.6M (est)Oxalo Therapeutics, Inc. · Pre-Seed Raised $250K · modeled $11.8M (est)Vin-5 Nob Hill Therapeutics, Llc (this company) Raised $113K · modeled $5.3M (est)Vin-5 Nob Hill Therapeutics, Llc
CompanyStageRaised · realValue · estvs peer med.
vivo-TIL Therapeutics, IncPre-Seed$990K$46.8M3.31×
JSK Therapeutics, Inc.Pre-Seed$963K$45.5M3.22×
Kyto Biopharma IncPre-Seed$845K$40.0M2.83×
Manzara Therapeutics, Inc.Pre-Seed$750K$35.5M2.51×
Mirata BioPharma, LLCPre-Seed$500K$23.7M1.67×
Avery Therapeutics, Inc.Pre-Seed$500K$23.7M1.67×
Senolytic Therapeutics, Inc.Pre-Seed$500K$23.7M1.67×
Chaperone Therapeutics, Inc.Pre-Seed$457K$21.6M1.53×
AR Pharma, Inc.Pre-Seed$410K$19.4M1.37×
Disrupt Pharma Tech Africa, Inc.Pre-Seed$330K$15.6M1.10×
Sante Veritas Therapeutics IncPre-Seed$267K$12.6M0.90×
Oxalo Therapeutics, Inc.Pre-Seed$250K$11.8M0.84×
Vin-5 Nob Hill Therapeutics, Llc this companyPre-Seed$113K$5.3M0.38×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$113K2016-10-26$625K$5.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$113K2016-10-26
    • First recorded raise — entered as Pre-Seed.
    • 13 investors on this round.
Intelligence
—
Modeled next raise
$180K
Modeled next size est.range $117K–$288K
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Mark Calvin Kidd—9 other2016-10
R. CALVIN GOFORTH—9 other2016-10
Registry & provenance

Vin-5 Nob Hill Therapeutics, Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1688879
SEC CIK
2016
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Vibliome Therapeutics, Inc.PharmaPre-Seed$113K$5.3Msame sector · same stage
Silver Therapeutics of Maine, LLCPharmaPre-Seed$120K$4.7Msame sector · same stage
OncoRock Therapeutics Inc.PharmaPre-Seed$125K$266Ksame sector · same stage
Sustained Therapeutics Inc.PharmaPre-Seed$100K$1.3Msame sector · same stage
Apie Therapeutics, Inc.PharmaPre-Seed$100K$4.2Msame sector · same stage
PiVista Therapeutics, Inc.PharmaPre-Seed$100K$2.5Msame sector · same stage
VIN-16 Neurexis Therapeutics, LLCPharmaPre-Seed$130K$5.6Msame sector · same stage
Tesseract Structural Innovations, Inc.OtherPre-Seed$788K$1.4Mnetwork2 shared operators · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Nob Hill Therapeutics, Inc.PharmaSeed$8.0M85%
VIN-16 Neurexis Therapeutics, LLCPharmaPre-Seed$5.6M80%
NV Therapeutics, Inc.PharmaSeed$12.8M76%
Zero Point Five Therapeutics, Inc.BiotechnologySeries A$15.7M76%
NOLA PharmaHoldings, LLCBiotech / PharmaSeries C$448.1M76%
Fleet Therapeutics, Inc.PharmaSeries B$508.2M74%
Mach5 Therapeutics, Inc.BiotechnologySeries B$119.5M74%
7 Hills Pharma Inc.PharmaceuticalsPre-Seed$4.9M74%
Frequently asked
How much funding has Vin-5 Nob Hill Therapeutics, Llc raised?
Vin-5 Nob Hill Therapeutics, Llc has raised approximately $113K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Vin-5 Nob Hill Therapeutics, Llc's estimated valuation?
Provath's modeled valuation for Vin-5 Nob Hill Therapeutics, Llc is approximately $5.3M (modeled range $63K–$60.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Vin-5 Nob Hill Therapeutics, Llc at?
Vin-5 Nob Hill Therapeutics, Llc's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Oct 26.
What does Vin-5 Nob Hill Therapeutics, Llc do and where is it based?
Vin-5 Nob Hill Therapeutics, Llc operates in the Pharma sector, based in FAYETTEVILLE.
Explore related

See where Vin-5 Nob Hill Therapeutics, Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Vin-5 Nob Hill Therapeutics, Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.